Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MMRC Horizon Two: A Phase II Randomized Adaptive Platform Trial Integrating Novel Therapies in High-Risk-Newly Diagnosed Multiple Myeloma (MMRC-100)

NCT07053436 is registered in ClinicalTrials.gov with Multiple Myeloma Research Consortium as lead sponsor.

NCT NCT07053436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07053436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MMRC Horizon Two: A Phase II Randomized Adaptive Platform Trial Integrating Novel Therapies in High-Risk-Newly Diagnosed Multiple Myeloma (MMRC-100)
Lead sponsor
Multiple Myeloma Research Consortium
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2026
Completion date
October 12, 2035
Enrollment
300 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

high risk newly diagnosed multiple myeloma